Amalgamated Bank Aerie Pharmaceuticals Inc Transaction History

Amalgamated Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$6.37 - $15.23 $1,082 - $2,589	170 Added 2.36%	7,370 $112,000
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $1,415 - $2,619	286 Added 4.14%	7,200 $54,000
Q1 2022 Jun 30, 2022	BUY	$5.64 - $9.8 $38,994 - $67,757	6,914 New	6,914 $63,000
Q3 2019 Nov 13, 2019	SELL	$18.41 - $28.0 $139,842 - $212,688	-7,596 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $63,878 - $106,303	2,205 Added 40.9%	7,596 $224,000
Q1 2019 May 15, 2019	BUY	$36.32 - $49.25 $195,801 - $265,506	5,391 New	5,391 $256,000
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $305,512 - $402,089	-5,441 Closed	0 $0
Q2 2018 Jul 18, 2018	BUY	$47.85 - $70.45 $43,352 - $63,827	906 Added 19.98%	5,441 $368,000
Q1 2018 May 22, 2018	BUY	$51.15 - $61.0 $3,222 - $3,843	63 Added 1.41%	4,535 $246,000
Q4 2017 Feb 13, 2018	BUY	$50.85 - $65.1 $14,543 - $18,618	286 Added 6.83%	4,472 $267,000
Q3 2017 Nov 09, 2017	BUY	$48.6 - $60.1 $203,439 - $251,578	4,186	4,186 $203,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.